GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (NSE:NECLIFE) » Definitions » Revenue

Nectar Lifesciences (NSE:NECLIFE) Revenue : ₹16,787 Mil (TTM As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Nectar Lifesciences Revenue?

Nectar Lifesciences's revenue for the three months ended in Sep. 2024 was ₹4,279 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₹16,787 Mil. Nectar Lifesciences's Revenue per Share for the three months ended in Sep. 2024 was ₹19.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₹73.60.

Warning Sign:

Nectar Lifesciences Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Nectar Lifesciences was 6.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -10.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Nectar Lifesciences's highest 3-Year average Revenue per Share Growth Rate was 22.90% per year. The lowest was -15.70% per year. And the median was 8.10% per year.


Nectar Lifesciences Revenue Historical Data

The historical data trend for Nectar Lifesciences's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Revenue Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23,663.79 15,432.97 16,688.32 15,236.70 16,840.86

Nectar Lifesciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,979.57 4,521.65 4,398.48 3,588.47 4,278.85

Competitive Comparison of Nectar Lifesciences's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Revenue distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Revenue falls into.



Nectar Lifesciences Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,787 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nectar Lifesciences  (NSE:NECLIFE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Nectar Lifesciences Revenue Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences Headlines

No Headlines